Oxford BioDynamics Plc

Equities

OBD

GB00BD5H8572

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:27 2024-04-26 am EDT			5-day change	1st Jan Change
8.1 ^GBX	-1.22%		-9.90%	-71.07%

Apr. 03	Oxford BioDynamics reaches "important milestone" with new laboratory	AN
Apr. 03	Oxford BioDynamics Plc Opens Clinical Testing Facility in the UK to Perform EpiSwitch Prostate Screening Blood Test	CI

Oxford BioDynamics director sells over 700,000 shares

October 20, 2023 at 05:34 am EDT

Oxford BioDynamics PLC - biotechnology company developing precision medicine tests based on the EpiSwitch 3D genomics platform - Reports that Vulpes Testudo Fund, controlled by Non-Executive Director Stephen Diggle has sold 777,000 shares of one pence each at an average price of 38.3p each. Diggle is now interested in 27.6 million shares in total, through the Vulpes Testudo and Vulpes Life Sciences Funds. These represent approximately 13.62% of Oxford BioDynamics's current issued share capital. Company's market capitalisation is GBP69.79 million.

Current stock price: 34.50 pence, up 1.5%

12-month change: up 70%

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about Oxford BioDynamics Plc

Oxford BioDynamics reaches "important milestone" with new laboratory	Apr. 03	AN
Oxford BioDynamics Plc Opens Clinical Testing Facility in the UK to Perform EpiSwitch Prostate Screening Blood Test	Apr. 03	CI
Oxford Biodynamics Raises GBP9.9 Million to Support EpiSwitch Product Line	Mar. 14	MT
FireAngel CFO resigns; ECR Minerals raises GBP585,000	Mar. 14	AN
EARNINGS AND TRADING: PensionBee nears profit; OptiBiotix Indian deal	Mar. 13	AN
Oxford BioDynamics plunges as annual loss widens; revenue up	Jan. 17	AN
Oxford BioDynamics plunge as annual profit rises; revenue up	Jan. 17	AN
Oxford BioDynamics shares plunge as annual revenue widens; revenue up	Jan. 17	AN
AIM WINNERS & LOSERS: James Cropper falls on lower outlook	Jan. 17	AN
Earnings Flash (OBD.L) OXFORD BIODYNAMICS Reports FY23 Revenue GBP510,000	Jan. 17	MT
Earnings Flash (OBD.L) OXFORD BIODYNAMICS Reports FY23 Loss GBX-7.30	Jan. 17	MT
Oxford BioDynamics Plc Reports Earnings Results for the Full Year Ended September 30, 2023	Jan. 17	CI
Oxford BioDynamics Appoints Steven Arrivo as Senior Vice President of Business and Corporate Development	Nov. 08	CI
FTSE 100 Edged Lower, Buoyed by Resilient Retail Sector	Nov. 07	DJ
Oxford BioDynamics director sells over 700,000 shares	23-10-20	AN
Oxford BioDynamics Strikes Deal with Bupa for Access to Blood Test	23-10-18	MT
Oxford BioDynamics in deal with Bupa to expand blood test access	23-10-18	AN
Oxford BioDynamics, Plc Announces a Strategic Agreement to Give Bupa Patients Access to OBD'sEpiSwitch CiRT	23-10-18	CI
AIM WINNERS & LOSERS: Safestyle plunges as seeks cash injection	23-10-03	AN
Oxford BioDynamics issued insurance reimbursement code for EpiSwitch	23-10-03	AN
Oxford BioDynamics soars as validates prostate test ahead of schedule	23-09-26	AN
Oxford Biodynamics Surges 92% With Early Launch of Prostate Screening Test	23-09-26	MT
Oxford BioDynamics Plc Launches 94% Accurate PSE Test in US and UK	23-09-26	CI
Oxford BioDynamics Plc Announces Validation of Its Episwitch Prostate Screening Test in Its US Clinical (CLIA-Certified) Laboratory Is Now Complete, Ahead of Schedule	23-09-26	CI
Oxford BioDynamics raises GBP540,000 in further equity raise	23-08-04	AN

Chart Oxford BioDynamics Plc

Duration

Period

More charts

Company Profile

Oxford BioDynamics Plc is a United Kingdom-based biotechnology company developing medicine tests for immune health based on the EpiSwitch 3D genomics platform. The Company is primarily engaged in the commercialization of proprietary molecular diagnostics products and biomarker research and development. Its products include EpiSwitch CiRT, EpiSwitch CST and EpiSwitch Explorer. The EpiSwitch CiRT is a blood test, which predicts an individual patientâs therapeutic response to checkpoint inhibitor immunotherapy. The EpiSwitch CST is a blood test for the prediction of COVID-19 severity in any adult. The EpiSwitch Explorer is a microarray kit for high-throughput, high-resolution 3D genome profiling. The EpiSwitch platform offers reproducibly translating 3D genome regulation for clinical application. This platform provides a portfolio of clinical smart tests based on EpiSwitch technology.

Sector

Biotechnology & Medical Research

Calendar

2024-05-27 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
OXFORD BIODYNAMICS PLC	-71.07%	20.41M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research